Sobrevida de mulheres com câncer de mama subtipo luminal assistidas em Juiz de Fora, Minas Gerais, Brasil

Abstract

Luminal breast cancer usually has a better prognosis in relation to other tumoral subtypes. Nonetheless, the illness in this point can evolve unfavorably in some circumstances what signals the need for a better understanding about this tumoral subtype behavior. The present study aimed at estimating the diseasefree survival of women with luminal breast cancer in five years. In this study, many variables have been evaluated, including prognostic, clinic, sociodemographic, histopathological and related to the use of public health services and treatment, aiming to get to know their impact and implications on recurrence and survival among the population of the study. The database was a hospital based cohort study, composed of 331 women diagnosed with the disease between 2003 and 2005, with immunohistochemical profile compatible with luminal breast cancer, non-metastatic (stages I, II or III), treated in a hospital seen as a reference for cancer care in Juiz de Fora, MG. The study showed a disease-free survival of 79.5% (IC95%: 74.6-83.6) in five years. The univariate analysis has shown an association of tumor recurrence with the type of health care, staging, tumor size, lymph node involvement and their number, chemotherapy and hormonal therapy (p<0.05) and it has indicated better survival rates among women who used private health care, who are in an initial stage, with smaller tumors, no axillary involvement and who used hormonal therapy. In the multivariate model, there remained gravity of the illness and the use of hormonal therapy as the most important prognostic factors. Molecular biology techniques represent the future for cancer treatment and also for luminal tumors. Access to hormonal therapy should be granted whenever prescribed and advanced stages must receive an amplified range of therapeutic approach.